There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > ORGANIZATION
ORGANIZATION
- JACDS Engaged in Petition Drive to Prevent Ban on “Dispensing Point” Services
December 9, 2011
- Shortest Development, Review Periods for New Drugs in 2010: OPIR Report
December 8, 2011
- FBRI to Open Nation’s Biggest Manufacturing Facility for Investigational PET Drugs
December 7, 2011
- PSUR to Be Renamed PBRER: ICH
December 5, 2011
- JACDS Council Holds Hearings on Remote Sales of OTC Drugs
December 2, 2011
- Original Drug Makers Should Let Go of Long-Listed Drugs
December 1, 2011
- Early Exploratory Studies Should Be Conducted in Japan for Japan-originated New Drugs: FPMAJ Chairman Shoda
December 1, 2011
- HGPI Holds Forum on Global Measures for NCD Issues
November 30, 2011
- Japanese Respiratory Foundation to Promote Research, Awareness of Respiratory Diseases
November 30, 2011
- Economic Losses Due to Illness, Injury Total ¥3.3 Tril. Annually in Japan: ACCJ
November 28, 2011
- MSF Japan General Director Expresses Concern Over TPP Negotiations, Possible Generics Price Rise
November 25, 2011
- SAMURAI Biotech Association Presents Petition to Health Minister Calling for NHI Pricing System Reflecting Economic Assessment
November 25, 2011
- JPMA, FPMAJ Call on LDP Council on Budget and Tax System with Requests for Next Year
November 24, 2011
- JACDS Discusses Problems Expected from Ban on Dispensing Point Services
November 21, 2011
- Plaintiffs Appeal to the Supreme Court: Iressa Appeal Trial
November 18, 2011
- 6 Indian Generics Companies Including Zydus Form Association, to Start Operations This Month
November 18, 2011
- JPMA Postpones Announcement of Views on TPP,“Will Not Comment Based on Speculation”
November 17, 2011
- Plaintiffs Say High Court Ruling over Iressa “Completely Denies Goals in Medical Administration”
November 17, 2011
- Top JPWA Officials Stress Importance of Wholesalers in Urgent Press Conference
November 17, 2011
- NEDO Decides to Provide Assistance to Four Projects to Develop Bio-Pharmaceutical Manufacturing Technology
November 16, 2011
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…